The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year ...

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Merck said it plans to make the drug available in the U.S. ahead of the upcoming RSV season. Enflonsia joins a growing arsenal of tools to prevent RSV in infants. Another option, the monoclonal ...